Podcasts

Articles

Webinars

Peer-Reviewed

Videos

CHEST

There are currently no FDA-approved treatments for refractory chronic cough or unexplained chronic cough. At the CHEST Annual Meeting 2021, attendees heard a readout from a durability study as well as pooled analyses from 2 phase 3 trials for gefapixant.

Additional Data on Possible Chronic Cough Therapy Presented at CHEST 2021

Evan L. Stepp, MD, FCCP, CPE, a pulmonologist at National Jewish Health, discusses an apparent change in attitudes among patients in the wake of 2019’s e-cigarette or vaping use–associated lung injury (EVALI) crisis.

Dr Evan Stepp: Patient Concern Over EVALI Appears to Have Faded 

There has been a huge shift forward in the understanding of innate and adaptive immune mechanisms that provoke type 2 inflammation in atopic disease and eosinophilic esophagitis, according to a CHEST Annual Meeting 2021 speaker.




Effects of Type 2 Inflammation in Allergic Disease: Visible, Invisible, Complex

Paradoxical bronchospasm, although rare, should be recognized more often in spirometry tests, said pulmonologist Malvika Kaul, MD, who discussed study findings from a population of veterans with chronic obstructive pulmonary disease (COPD) and asthma, where the possibly life-threatening condition was not picked up in lung tests. 

Dr Malvika Kaul: Paradoxical Bronchospasm Should Be More Recognized in COPD, Asthma

Nicole Herbst, MD, a pulmonary and critical care fellow, talks about how visitor restrictions and communication practices in intensive care units (ICUs) during the COVID-19 pandemic negatively impacted provider job satisfaction and were linked to job burnout, according to a survey presented at the CHEST Annual Meeting 2021.










Dr Nicole Herbst on the Effect of ICU Visitor Restrictions on Provider Burnout

A panel discussion at the CHEST Annual Meeting 2021 discussed disparities related to race, ethnicity, gender, and socioeconomic status that have been shown to impact access to high-quality lung cancer care.

Addressing Disparities in Uptake, Screening, and Research for Lung Cancer Care

At a session of the CHEST Annual Meeting 2021, specialists reviewed the need for a thorough diagnosis to tell whether a patient's symptoms are caused by asthma or another pulmonary condition.

Distinguishing Asthma From Other Pulmonary Diseases

Researchers at the CHEST Annual Meeting 2021 addressed the evolution of COVID-19 variants, how these emerging strains impact vaccines, and preventive recommendations for at-risk populations.

Understanding Evolving Variants, Vaccines, and Treatment for COVID-19

There are several reasons as to why precision therapeutics have not taken off for chronic obstructive pulmonary disease (COPD) in the same way that they have for other diseases, said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.


Dr Don Sin on the Barriers to Precision Medicine for COPD

Panelists of a session at CHEST 2021 discuss the latest research regarding efficacy and safety of therapies in the management of asthma, including biologics, corticosteroids, and more.